AR109451A1 - Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión - Google Patents
Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresiónInfo
- Publication number
- AR109451A1 AR109451A1 ARP170101019A ARP170101019A AR109451A1 AR 109451 A1 AR109451 A1 AR 109451A1 AR P170101019 A ARP170101019 A AR P170101019A AR P170101019 A ARP170101019 A AR P170101019A AR 109451 A1 AR109451 A1 AR 109451A1
- Authority
- AR
- Argentina
- Prior art keywords
- rrs
- vector
- nucleic acid
- vectors
- different
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000013598 vector Substances 0.000 abstract 20
- 108020004707 nucleic acids Proteins 0.000 abstract 14
- 102000039446 nucleic acids Human genes 0.000 abstract 14
- 150000007523 nucleic acids Chemical class 0.000 abstract 14
- 102100030355 Host cell factor 1 Human genes 0.000 abstract 6
- 239000002773 nucleotide Substances 0.000 abstract 5
- 125000003729 nucleotide group Chemical group 0.000 abstract 5
- 102000025171 antigen binding proteins Human genes 0.000 abstract 4
- 108091000831 antigen binding proteins Proteins 0.000 abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 238000005215 recombination Methods 0.000 abstract 2
- 230000006798 recombination Effects 0.000 abstract 2
- 238000001890 transfection Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Una célula que comprende, un primer ácido nucleico exógeno integrado dentro de un primer locus de expresión mejorada; y un segundo ácido nucleico exógeno integrado dentro de un segundo locus de expresión mejorada; en donde el primer y el segundo ácido nucleico exógeno codifican juntos una proteína de unión a antígeno. Reivindicación 32: Un conjunto de vectores para expresar una proteína de unión a antígeno biespecífica en una célula, que comprende: un primer vector que comprende, de 5 a 3, un primer RRS, un primer ácido nucleico que comprende una secuencia de nucleótidos que codifica un primer HCF, y un segundo RRS; un segundo vector que comprende, de 5 a 3, un tercer RRS, un segundo ácido nucleico que comprende una secuencia de nucleótidos que codifica una segunda HC, un cuarto RRS; y una secuencia de nucleótidos que codifica una primera LC que está dentro del primer ácido nucleico en el primer vector, o está en un tercer vector diferente del primer y el segundo vector; en donde el primer, el segundo, el tercer y el cuarto RRS son diferentes; y en donde la proteína de unión a antígeno biespecífica comprende el primer HCF, el segundo HCF y el primer LCF, y en donde el primer y el segundo HCF son diferentes. Reivindicación 51: Un sistema que comprende una célula y un conjunto de vectores, en donde la célula comprende, integrado dentro de un primer locus de expresión mejorada: de 5 a 3, un primer RRS, un primer ácido nucleico exógeno y un segundo RRS; integrado dentro de un segundo locus de expresión mejorada: de 5 a 3, un tercer RRS, un segundo ácido nucleico exógeno y un cuarto RRS; en donde el primer y el segundo RRS son diferentes, y el tercer y el cuarto RRS son diferentes; y en donde el primer y el segundo loci de expresión mejorada son diferentes; en donde el conjunto de vectores comprende, un primer vector que comprende, de 5 a 3, un primer vector RRS 5, un primer ácido nucleico y un primer vector RRS 3, en donde el primer vector RRS 5 y 3 son diferentes; un segundo vector que comprende, de 5 a 3, un segundo vector RRS 5, un segundo ácido nucleico y un segundo vector RRS 3, en donde el segundo vector RRS 5 y 3 son diferentes; una secuencia de nucleótidos que codifica un primer HCF y una secuencia de nucleótidos que codifica un primer LCF, en donde una de las secuencias de nucleótidos está en el primer ácido nucleico y las otras secuencias de nucleótidos están en el segundo ácido nucleico; en donde el primer HCF y el primer LCF son regiones de una proteína de unión a antígeno; y en donde, tras la introducción de los vectores en la célula, el primer y el segundo ácido nucleico en los vectores se integran en el primer locus de expresión mejorada y el segundo locus de expresión mejorada, respectivamente, a través de la recombinación mediada por los RRS. Reivindicación 78: Un método que comprende: (i) proporcionar un sistema de acuerdo con una cualquiera de las reivindicaciones 51 - 77; (ii) introducir los vectores en la célula por transfección; y (iii) seleccionar una célula transfectada donde los ácidos nucleicos en los vectores se han integrado en el primer y el segundo loci de expresión mejorada a través de la recombinación mediada por los RRS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325400P | 2016-04-20 | 2016-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109451A1 true AR109451A1 (es) | 2018-12-12 |
Family
ID=58701851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101019A AR109451A1 (es) | 2016-04-20 | 2017-04-20 | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11512144B2 (es) |
| EP (1) | EP3445781A1 (es) |
| JP (3) | JP7096770B2 (es) |
| KR (2) | KR102547738B1 (es) |
| CN (2) | CN116515757A (es) |
| AR (1) | AR109451A1 (es) |
| AU (2) | AU2017253241B2 (es) |
| BR (1) | BR112018071283A2 (es) |
| CA (1) | CA3015389A1 (es) |
| EA (1) | EA201892010A1 (es) |
| IL (2) | IL314779A (es) |
| MX (1) | MX2018012868A (es) |
| SG (2) | SG10202010155YA (es) |
| TW (2) | TWI827531B (es) |
| WO (1) | WO2017184832A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3015389A1 (en) * | 2016-04-20 | 2017-10-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of expression-enhancing loci |
| AU2018392728A1 (en) * | 2017-12-22 | 2020-07-09 | Genentech, Inc. | Targeted integration of nucleic acids |
| KR20210107057A (ko) * | 2018-12-21 | 2021-08-31 | 제넨테크, 인크. | 핵산의 표적화 통합 |
| CA3134705A1 (en) * | 2019-04-02 | 2020-10-08 | Chugai Seiyaku Kabushiki Kaisha | Method of introducing target-specific foreign gene |
| AU2020308002A1 (en) | 2019-06-26 | 2022-01-20 | Genentech, Inc. | Randomized configuration targeted integration of nucleic acids |
| CN118451189A (zh) | 2021-10-18 | 2024-08-06 | 瑞泽恩制药公司 | 包括用于产生稳定整合位点的整合的cas9基因的哺乳动物细胞，以及包括稳定整合位点和其它位点的哺乳动物细胞 |
| TW202323529A (zh) | 2021-10-18 | 2023-06-16 | 美商再生元醫藥公司 | 包括腺病毒相關病毒聚核苷酸的真核細胞 |
| IL312148A (en) | 2021-10-18 | 2024-06-01 | Regeneron Pharma | Controlled transcription of polynucleotides |
| KR20240117146A (ko) * | 2021-12-22 | 2024-07-31 | 제넨테크, 인크. | 다중 벡터 재조합효소 매개 카세트 교환 |
| WO2023238949A1 (ja) * | 2022-06-10 | 2023-12-14 | 富士フイルム株式会社 | 細胞の作出方法、ヘテロ多量体タンパク質の製造方法、バイスペシフィック抗体の製造方法、ベクターセット、哺乳動物細胞、ｃｈｏ細胞、及び細胞プールの作出方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
| DK1531666T3 (da) | 2002-05-29 | 2014-01-13 | Regeneron Pharma | Inducerbart eukaryot-ekspressionssystem |
| US20050019925A1 (en) | 2002-11-14 | 2005-01-27 | Genentech, Inc. | Intron fusion construct and method of using for selecting high-expressing production cell lines |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| JP5474531B2 (ja) | 2006-03-24 | 2014-04-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 操作されたヘテロ二量体タンパク質ドメイン |
| PL2041177T3 (pl) | 2006-06-02 | 2012-09-28 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| EP2115136A4 (en) | 2006-12-21 | 2010-05-19 | Glaxosmithkline Llc | NOVEL PROCEDURE |
| WO2008089396A1 (en) | 2007-01-19 | 2008-07-24 | Invitrogen Corporation | Compositions and methods for genetic manipulation and monitoring of cell lines |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| WO2008151219A1 (en) * | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| HUE028536T2 (en) | 2008-01-07 | 2016-12-28 | Amgen Inc | Method for producing antibody to FC heterodimer molecules using electrostatic control effects |
| HUE038596T2 (hu) * | 2009-06-02 | 2018-10-29 | Regeneron Pharma | Fukoziláció-hiányos sejtek |
| EP3916011A1 (en) | 2009-06-26 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2781519A1 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| KR20120099376A (ko) | 2009-09-18 | 2012-09-10 | 셀렉시스 에스. 에이. | 강화된 전이 유전자 발현과 공정 방법 및 그 산물 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| MX338953B (es) | 2010-08-16 | 2016-05-06 | Novimmune Sa | Metodos para la generacion de anticuerpos multiespecificos y multivalentes. |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) * | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| WO2014022540A1 (en) * | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI675044B (zh) | 2012-11-14 | 2019-10-21 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MX2017005306A (es) | 2014-10-23 | 2018-01-09 | Regeneron Pharma | Novedosos sitios de integracion en celulas cho y usos de estos. |
| ES2901133T3 (es) | 2015-09-23 | 2022-03-21 | Regeneron Pharma | Anticuerpos biespecíficos anti-CD3 optimizados y usos de los mismos |
| CA3015389A1 (en) * | 2016-04-20 | 2017-10-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of expression-enhancing loci |
-
2017
- 2017-04-20 CA CA3015389A patent/CA3015389A1/en active Pending
- 2017-04-20 BR BR112018071283A patent/BR112018071283A2/pt unknown
- 2017-04-20 AU AU2017253241A patent/AU2017253241B2/en active Active
- 2017-04-20 US US16/095,084 patent/US11512144B2/en active Active
- 2017-04-20 KR KR1020187029365A patent/KR102547738B1/ko active IP Right Grant
- 2017-04-20 IL IL314779A patent/IL314779A/en unknown
- 2017-04-20 SG SG10202010155YA patent/SG10202010155YA/en unknown
- 2017-04-20 EA EA201892010A patent/EA201892010A1/ru unknown
- 2017-04-20 MX MX2018012868A patent/MX2018012868A/es unknown
- 2017-04-20 IL IL262266A patent/IL262266B1/en unknown
- 2017-04-20 EP EP17723183.4A patent/EP3445781A1/en active Pending
- 2017-04-20 CN CN202211606177.7A patent/CN116515757A/zh active Pending
- 2017-04-20 TW TW106113298A patent/TWI827531B/zh active
- 2017-04-20 JP JP2018552794A patent/JP7096770B2/ja active Active
- 2017-04-20 KR KR1020237020953A patent/KR20230098361A/ko not_active Application Discontinuation
- 2017-04-20 CN CN201780024557.0A patent/CN109195986B/zh active Active
- 2017-04-20 AR ARP170101019A patent/AR109451A1/es unknown
- 2017-04-20 TW TW112130927A patent/TW202415767A/zh unknown
- 2017-04-20 WO PCT/US2017/028555 patent/WO2017184832A1/en active Application Filing
- 2017-04-20 SG SG11201807885PA patent/SG11201807885PA/en unknown
-
2021
- 2021-07-09 JP JP2021114374A patent/JP2021164479A/ja active Pending
-
2022
- 2022-09-28 US US17/936,059 patent/US20230130799A1/en active Pending
-
2023
- 2023-11-29 JP JP2023201924A patent/JP2024023449A/ja active Pending
-
2024
- 2024-09-26 AU AU2024220124A patent/AU2024220124A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201803986A (zh) | 2018-02-01 |
| JP2019515666A (ja) | 2019-06-13 |
| IL262266B1 (en) | 2024-09-01 |
| US20190233544A1 (en) | 2019-08-01 |
| CN116515757A (zh) | 2023-08-01 |
| EP3445781A1 (en) | 2019-02-27 |
| KR20180134893A (ko) | 2018-12-19 |
| WO2017184832A1 (en) | 2017-10-26 |
| US11512144B2 (en) | 2022-11-29 |
| BR112018071283A2 (pt) | 2019-02-12 |
| JP2024023449A (ja) | 2024-02-21 |
| KR20230098361A (ko) | 2023-07-03 |
| JP7096770B2 (ja) | 2022-07-06 |
| TW202415767A (zh) | 2024-04-16 |
| CN109195986B (zh) | 2023-01-03 |
| CN109195986A (zh) | 2019-01-11 |
| AU2024220124A1 (en) | 2024-10-17 |
| KR102547738B1 (ko) | 2023-06-26 |
| US20230130799A1 (en) | 2023-04-27 |
| IL262266A (en) | 2018-11-29 |
| SG11201807885PA (en) | 2018-10-30 |
| EA201892010A1 (ru) | 2019-03-29 |
| AU2017253241B2 (en) | 2024-07-04 |
| MX2018012868A (es) | 2019-03-11 |
| IL314779A (en) | 2024-10-01 |
| JP2021164479A (ja) | 2021-10-14 |
| CA3015389A1 (en) | 2017-10-26 |
| TWI827531B (zh) | 2024-01-01 |
| AU2017253241A1 (en) | 2018-09-20 |
| SG10202010155YA (en) | 2020-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109451A1 (es) | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión | |
| CL2021002742A1 (es) | Una proteína crispr de prevotella y francisella 1 (cpf1) aislada de francisella tularensis; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004) | |
| MX2021011697A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123. | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| MX2021015033A (es) | Clasificacion con contraseleccion utilizando peptidos de secuencias similares. | |
| NZ756132A (en) | Method for producing multispecific antibodies | |
| PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| BR112019008675A2 (pt) | roedor, célula isolada de roedor, e, métodos de produção de um roedor e de um anticorpo em um roedor. | |
| EP4223873A3 (en) | Compositions and methods for t cell delivery of therapeutic molecules | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| PE20180481A1 (es) | Anticuerpos de union a tau | |
| ECSP22015276A (es) | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| MA40929A (fr) | Procédé de production d'anticorps à affinité élevée | |
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| MX2019002307A (es) | Anticuerpos multiespecificos que facilitan el emparejamiento selectivo de cadenas ligeras. | |
| RU2014102617A (ru) | Выявление аффинно-зрелых человеческих антител | |
| AR124933A2 (es) | Molécula de ácido nucleico aislada, vector aislado y célula cho aislada y modificada que es incapaz de regenerar en un individuo completo | |
| CY1123363T1 (el) | Απομονωση νουκλεϊνικων οξεων | |
| AR124084A1 (es) | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO | |
| EA202091713A1 (ru) | Биологический синтез аминокислотных цепей для получения пептидов и белков | |
| MX2016012525A (es) | Anticuerpo anti-grpr, proceso de obtencion, proceso de deteccion, uso de anticuerpo, kit y construccion genetica. | |
| EA202193234A1 (ru) | Сортировка с контрселекцией с применением пептидов со сходными последовательностями | |
| Faridi | Solving the spliced-peptides mystery by using machine learning techniques | |
| EA202192299A1 (ru) | Библиотеки вариантных нуклеиновых кислот для оптимизации антител |